Most Q4 2021 Activity in ESG Seen in Environmental Initiatives Compared to Social or Governance: In Q4 2021, no major social or governance sustainability activity was detected, however many companies announced new environmental initiatives. For example, AstraZeneca was the only pharma company to have its net zero targets verified by Science Based Targets in line with its new Net Zero Standard. At the 26th United Nations (UN) Climate Change Conference (COP26), the company was also named as one of the first holders of the Terra Carta Seal in recognition of its sustainability efforts, and it was also announced that AstraZeneca was one of 10 pharma companies in the Energize program, a collaboration that supports decarbonization of pharma value chains. Sanofi announced that it had joined the UN’s Race to Zero initiative, which aims to get cities, regions, investors, and top companies to commit to net zero carbon emissions by 2050. Teva issued a sustainability bond linked to both social and environmental targets. GSK announced a significant investment in renewable energy and carbon reduction at manufacturing sites, as well as a new initiative to reduce GHG emissions from its inhalers. Astellas announced that it had begun using biomass-based plastics in blister packages for its products.
Artificial Intelligence, Virtual Care, Cybersecurity, and Real-World Evidence Also Saw Activity in Q4 2021: Many companies included in the Clinical Trials scorecard have announced partnerships in the artificial intelligence (AI) space since September 2021. This includes collaborations between Gilead and Amazon Web Services (AWS), Roche and Recursion Pharma, Sanofi and Deloitte, and AstraZeneca with Tempus and with Oncoshot. In virtual care, companies including AbbVie, Sanofi, Eli Lilly, Boehringer Ingelheim, and Biogen posted several jobs relating to virtual trials and initiated trials with virtual components in Q4 2021. Similarly, Sanofi, Johnson & Johnson (J&J), Merck & Co, and Pfizer posted high numbers of jobs relating to cybersecurity in Q4 2021. In real-world evidence (RWE), Merck & Co announced a new collaboration with Syapse to leverage real-world data (RWD) in oncology.
GlobalData’s Clinical Trials Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the clinical trial sector over the next two to four years.
These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
The scorecard includes 54 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
It is important to note that this scorecard is not an assessment of current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
The methodology section contains information on what data sources were used to generate the thematic scores for each company.
The scorecard is live on the PIC and will be updated quarterly.
Reasons to Buy
Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
Understand which key themes should be addressed to drive share price.
Understand which companies are best positioned for success within critical themes and why.
Learn which companies have underinvested in key themes and are most vulnerable to disruption.
Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
Help identify future winners and losers in drug development to inform partnership strategies.
Takeda Pharmaceutical Co Ltd
Merck & Co Inc
Bristol-Myers Squibb Co
Johnson & Johnson
Parexel International Corp
F. Hoffmann-La Roche Ltd
Eli Lilly and Co
IQVIA Holdings Inc
Novo Nordisk AS
Gilead Sciences Inc
Thermo Fisher Scientific Inc
Lonza Group Ltd
Daiichi Sankyo Co Ltd
Vertex Pharmaceuticals Inc
WuXi AppTec Co Ltd
Charles River Laboratories International Inc
Reliance Life Sciences Pvt Ltd
Innovent Biologics Inc
Teva Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Sun Pharmaceutical Industries Ltd
Cadila Pharmaceuticals Ltd
Coherus BioSciences Inc
CSPC Pharmaceutical Group Ltd
Intas Pharmaceuticals Ltd
Perrigo Co Plc
Pharmaceutical Product Development LLC
Shanghai Henlius Biotech Inc
Table of Contents
• Pharma Theme Map
Clinical Trials Scorecard: Key Q4 2021 Updates
• Company Screen
• Thematic Screen
• Valuation Screen
Our Thematic Research Methodology
• How Our Pharma Scores Are Generated
About the Authors